AC Immune (ACIU) Cash & Equivalents (2014 - 2026)

AC Immune (ACIU) has 13 years of Cash & Equivalents data on file, last reported at $24.5 billion in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 110162.74% year-over-year to $24.5 billion in Q1 2026; TTM through Mar 2026 was $24.5 billion, a 110162.74% increase from a year earlier, with the FY2025 full-year figure at $32.3 million, down 21.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $24.5 billion, up from $33.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ACIU reached as high as $24.5 billion in Q1 2026 and fell as low as $62624.2 in Q1 2022.
• Historically, Cash & Equivalents has averaged $1.5 billion across 5 years, with a median of $37.4 million in 2024.
• Across the five-year window, Cash & Equivalents tumbled 66.01% in 2025 and jumped 110162.74% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $32.8 million in 2022, then soared by 169.9% to $88.5 million in 2023, then tumbled by 53.21% to $41.4 million in 2024, then retreated by 19.04% to $33.5 million in 2025, then soared by 72916.66% to $24.5 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $24.5 billion in Q1 2026, $33.5 million in Q4 2025, and $34.7 million in Q3 2025.